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Cultured Endothelial Cells Produce a Heparinlike
Inhibitor of Smooth Muscle Cell Growth
ABSTRACT
￿
Using cultured cells from bovine and rat aortas, we have examined the possibility
that endothelial cells might regulate the growth of vascular smooth muscle cells. Conditioned
medium from confluent bovine aortic endothelial cells inhibited the proliferation of growth-
arrested smooth muscle cells. Conditioned medium from exponential endothelial cells, and
from exponential or confluent smooth muscle cells and fibroblasts, did not inhibit smooth
muscle cell growth. Conditioned medium from confluent endothelial cells did not inhibit the
growth of endothelial cells or fibroblasts. In addition to the apparent specificity of both the
producer and target cell, the inhibitory activity was heat stable and not affected by proteases.
It was sensitive to Flavobacterium heparinase but not to hyaluronidase or chondroitin sulfate
ABC lyase. It thus appears to be a heparinlike substance. Two other lines of evidence support
this conclusion . First, a crude isolate of glycosaminoglycans (TCA-soluble, ethanol-precipitable
material) from endothelial cell-conditioned medium reconstituted in 20% serum inhibited
smooth muscle cell growth; glycosaminoglycans isolated from unconditioned medium (i.e.,
0.4% serum) had no effect on smooth muscle cell growth . No inhibition was seen if the
glycosaminoglycan preparation was treated with heparinase . Second, exogenous heparin,
heparan sulfate, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate ABC, and hyalu-
ronic acid were added to 20% serum and tested for their ability to inhibit smooth muscle cell
growth. Heparin inhibited growth at concentrations as low as 10 ng/ml. Other glycosamino-
glycans had no effect at doses up to 10
tug/ml .
Anticoagulant and non-anticoagulant heparin
were equally effective at inhibiting smooth muscle cell growth, as they were in vivo following
endothelial injury (Clowes and Karnovsk. Nature (Lond.) . 265:625-626,1977; Guyton et al . Circ.
Res. 46:625-634, 1980), and in vitro following exposure of smooth muscle cells to platelet
extract (Hoover et al. Circ. Res. 47:578-583, 1980). We suggest that vascular endothelial cells
may secrete a heparinlike substance in vivo which may regulate the growth of underlying
smooth muscle cells.
A characteristic feature of the normal, healthy arterial wall is
that the intimal endothelial cells form a continuous quiescent
monolayer, and the underlying medial smooth muscle cells
also remain in a quiescent growth state. If the endothelium is
damaged, smooth muscle cell proliferation occurs until the
endothelium regenerates (9, 29). The regulation of cell growth
in the vascular wall is poorly understood. Ross (15, 28) and
others (10, 25) have shown that platelet-derived growth factors
are required for smooth muscle cell growth in vivo and in vitro.
Recently, conditioned medium from macrophages has been
found to stimulate smooth muscle cells (23). Gajdusek et al.
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(11) have shown that endothelial cells produce a factor which
stimulates the growth of smooth muscle cells. Eisenstein et al.
(8) have found that extracts from the inner arterial wall can be
fractionated to produce both stimulators and inhibitors of
smooth muscle cell growth.
We present evidence demonstrating that cultured endothelial
cells produce both positive and negative effectors of smooth
muscle cell growth. The inhibitory activity appears to be hep-
arin or a heparinlike molecule. These results suggest a possible
role for heparin in the regulation of vascular smooth muscle
cell growth in vivo.
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Purification of Heparinase
Flavobacterium heparinam were either grown as described by Linker and
Hovingh (22) or were provided by Dr. R. Langer (Massachusetts Institute of
Technology, Boston, Mass). Thecells were sonicated at a cell protein concentra-
tion of -8 mg/ml for 12 min with a Branson Sonifier set at 125 W. Thesonicate
was centrifuged at 20,000 g at 4°C for 30 min. The resulting supernate was
treated with protamine sulfate at a level of 15 mg/ml and then exhaustively
dialyzed against distilled water.
Thecrude preparationwas subsequentlychromatographed on hydroxylapatite
and cellulose-phosphate as outlined by Linker and Hovingh (22). We purified
the enzyme further by concentrating with ultrafiltration, and then by filtration
on Sephacryl S-200 equilibrated in 0.5 MNaCl in 0.01 MTris-HCl, pH 7.5. The
elution profile exhibited a major protein peak at a molecular weight of -60,000
daltons, as well as several minor protein peaks of lower molecular size. Direct
analysis ofthe first peak with respect to heparin-cleaving potency (22) revealed
a constant specific activity of 3,000 U/mg across the initial two-thirds of the
profile. The remaining two components oflower molecular size possessed essen-
tially no glycosaminoglycan (GAG)-cleaving ability. Thefinal enzyme prepara-
tion exhibited no capacity to degrade chondroitin sulfate, dermatan sulfate, or
hyaluronic acid when employed at concentrations as high as -200 pg/ml (24).
There was no detectable protease activity in this preparation as measured by the
radiolabeled casein assay (17).
Isolation of Bovine Aortic Heparan Sulfate
Glycosaminoglycans were obtained from bloodvesselsby extensive proteolytic
digestion ofthe intima and mediaofcalfaortas (26). Heparan sulfate was isolated
free ofotherGAGSbychromatographyon DEAF-Sephadex A-25 andSepharose
4B (30). Theresulting product was identified by the two-dimensional electropho-
retic system of Hata and Nagai (16) in conjunction with appropriate standards.
The nature of the heparan sulfate was confirmed by its sensitivity to digestion
with bacterial heparinase and its resistance to the action ofchondroitinase ABC
and testicular hyaluronidase (24).
Cell Culture
Bovine aortic endothelial cells (BAEC) were isolated from freshly slaughtered
calves, as previously described (2, 13, 19). The cells obtained from one aorta are
grown in a single 75-cm' tissue culture flask in RPMI-1640 medium containing
20% fetal calf serum (FCS), 4 mM glutamine, penicillin (100U/ml), streptomycin
(100 pg/ml), amphotericin (0.25 pg/ml), and gentamicin (50 pg/ml) at 37 °C in
a humidified, 10% C02 atmosphere. At confluence, >95% of the cells are
endothelial, as determined by their distinctive morphology and the presence of
factor VIII antigen on the cell surface.
Rat aorta smooth muscle cells (rat SMC) from Sprague-Dawley (Charles
River, Wellesley, Mass.; CD strain) rats were isolated (18) aspreviously described.
Cells were grown in the same medium and incubation conditions described for
BAEC.
Calf aorta smooth muscle cells (calf SMC) were isolated as previously de-
scribed (27). Cells were grown in Dulbecco's modified Eagle's medium (DMEM)
containing 10% calf serum (CS), penicillin (100 U/ml), streptomycin (100 ttg/
ml), amphotericin (0.25 pg/ml), and gentamicin (50 pg/ml) at 37°C in a humid-
ified, 10% C02 atmosphere.
Baby hamster kidney-21/clone 13 cells (BHK) were obtained from the
American Type Culture Collection (Rockville, Md.). Cells were grown in DMEM
containing 10% FCS, penicillin (100 U/ml), streptomycin (100 pg/ml), and
gentamicin (50 pg/ml) at 37°C in a humidified, 10% COs atmosphere. This
fibroblast line was used because many laboratories have shown that these cells
can be readily growth-arrested, and that the growth ofthe cells is dependent on
serum factors. Thus its growth characteristics are similar to those of smooth
muscle cells.
Conditioned Medium
Aweek or more after reaching confluence, BAEC were washed and 10 ml (-l
ml/10' cells) of RPMI containing 0.4% FCS was added. 48 hlater, this medium
was removed and immediately filtered through a 0.22 pin filter. Conditioned
medium (CM) from exponential BAEC and from exponential and confluent
cultures ofother cell types was collected in the same manner. Before adding it to
cells, CM was mixed 1:1 with medium containing twice the usual serum concen-
tration (e.g., RPMI + 40% FCS, or DMEM + 20% CS), thus yielding a final
serum concentration of 20%and 10%, respectively.
Growth Arrest of SMC
Sparsely plated rat or calf SMC were washed and placed in RPMI + 0.4%
FCS or DMEM + 0.2% CS for 72 h. Flow microfluorimetry (32) and [''H]-
thymidine uptake into DNA were used to determine that the cells were arrested
in Go (GI).
Inhibition Assay
To assay for inhibitory activity, 6x 10' cells were platedinto 16-mmmultiwell
plates and growth-arrested as described above. Control cultures were released
from the G block by placing them in RPMI + 20% FCS. Other cultures were
placed in the 1 :1 mixture of CM and RPMI + FCS (final concentration FCS
20%). Cell numbers were measured in duplicate samples at daily intervals by
washing the cells once in a trypsin-EDTA solution (Grand Island Biological Co.,
Grand Island, N. Y.), then incubating the cells for several minutes in trypsin-
EDTA solution to dislodge the cells. The dislodged cells were collected and
counted in a Coulter counter. Trypsinized cultures were routinely checked by
direct microscopic examination to ascertain that the trypsinization procedurehad
not lysed the cells (as determined by the presence of cell debris) and to ensure
that all cells were removed from the multiwell. Thecells were not fed during the
experiment.
Mitogenesis Assay
To assay for mitogenic activity, exponential BAEC-CM was fractionated and
concentrated 50-fold using Amicon XM100 and UM10 filters (Amicon Corp.,
Scientific Sys. Div., Lexington, Mass.). A concentrated fraction was mixed 1:1
with RPMI + FCS (final concentration FCS 1%) and added to growth-arrested
rat SMC. In some control experiments, cells were exposed to a 1: I mixture of50-
fold concentrated RPMI + 0.4% FCS and RPMI + FCS (final concentration
FCS 1%). In other control experiments, cells received RPMI + 20% FCS. Cell
numbers were measured in duplicate samples at daily intervals using a Coulter
counter as described above.
Chemicals
Chondroitin sulfate ABC lyase and Streptomyces hyaluronidase were pur-
chased from Miles Laboratories Inc., Miles Research Products (Elkhart, Ind).
Unless otherwise stated, heparin was obtained from Upjohn Co., Agricultural
Prods. MKT(Kalamazoo, Mich.) or Elkins-Sinn, Inc. (Cherry Hill, N. J.); other
GAGS were kindly supplied by Drs. M. Mathews and J. Cifonelli (University of
Chicago). All other chemicals were obtained from Sigma Chemical Co. (St.
Louis, Mo.).
RESULTS
Growth Arrest of SMC
SMC were plated and exposed to low serum as described in
Materials and Methods. We used flow microfluorimetry and
[3Hlthymidine uptake into DNA to determine the cell cycle
distribution of exponentially growing and serum-deprived
SMC (32). The results will be published in detail elsewhere.'
In brief, >90% of the growth-arrested rat SMC cells have the
G 1 DNA content. These cells are most likely arrested at the
same point in the cell cycle (Go), because growth-arrested cells
placed in fresh complete medium undergo a synchronous round
of DNA synthesis, with the earliest cells beginning S phase 16-
18 h after the addition of serum. The peak of DNA synthesis
occurs -28 h after release. Flow microfluorimetry confirms the
time course of this release from Go. Calf SMC behaved simi-
larly, except that the onset of S phase began 12-14 h after
release, and peaked at -20 h.
Effect of Confluent Primary BAEC-CM on SMC
Rat and calf SMC were growth-arrested as described in
Materials and Methods. Control cultures were released from
the Go block by replacing the low serum medium with RPMI
' Castellot, J., and M. J. Kamovsky. Manuscript in preparation.
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confluent primary BAEC-CM and RPMI + FCS (final con-
centration FCS 20%). Cell growth after exposure to CM is
presented in Fig. 1.
Rat SMC exposed to CM go through one to one and a half
doublings at the same rate as control cells. After this initial
growth, rat SMC stopped proliferating. Control cultures reach
confluence at day 4 or 5 under these conditions. If the CM was
replaced with normal growth medium at day 4 or 5, the cells
proliferated to confluence.
CalfSMC exposed to CM also go through one or two rounds
ofdivision at about the same rate as control cells. At this point
(usually day 3), the cells in CM often began to round up and
slowly detach. Very few cells remained by day 5. Once the cells
began to round up, replacing the CM with normal growth
medium did not reverse this effect. In approximately one-third
of the experiments, the calf SMC did not round up, but their
growth plateaued, as shown in Fig. 1 . The inhibitory effect was
reversible, as the cells in these experiments proliferated to
confluence if the CM was replaced with normal growth me-
dium.
Direct observation of cells undergoing mitosis in CM-ex-
posed rat and calf SMC cultures revealed that both daughter
cells remained attached and spread normally aftercytokinesis.
Neither visual inspection nor Coulter counting of the medium
indicated the presence of detached cells in CM-treated rat
SMC and calf SMC cultures in which the cells did not round
up. Flow microfluorimetry data indicate that both CM-treated
and control SMC were arrested mainly in Go (GI) at the
endpoint of the experiment(data not shown). CM-treated SMC
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FIGURE 1
￿
Effect of CM from confluent primary BAEC on growth-
arrested SMC. Rat and calf SMC were arrested in Go by serum-
deprivation as described in Materials and Methods. The effect of
confluent primary BAEC-CM on SMC growth was assayed as de-
scribed in Materials and Methods. In approximately two thirds of
the experiments, calf SMC exposed to CM began to round up and
detach at day 3 (A-"). The other third of the time, the calf SMC
did not round up ("---") . A-0, calf SMC in RPMI + 20% FCS;
C--O, rat SMC in RPMI + 20% FCS; "--", rat SMC exposed to
CM. Data for each cell type are the average of ten or more experi-
ments.
374
￿
THE JOURNAL OF CELL BIOLOGY " VOLUME 90, 1981
did not stain with trypan blue at any time during the course of
the experiment. Finally, the possibility that the detachment of
calf SMC is related to something present in the serum is
suggested by experiments in which CM was mixed 1 :1 with
lower concentrations of FCS (final FCS concentrations, 10%
and 5%). In these experiments, growth of control calf SMC
(i.e., no CM) is reduced to three to four doublings in 10% FCS
and two to three doublings in 5% FCS. CM-treated calf SMC
did not go through even one doubling, and they did not round
up and detach. Because of the potential difficulties in quanti-
fying results of experiments in which calf SMC detached,
subsequent data on calf SMC in this paper are based on
experiments in which calf SMC did not round up and detach.
To test the possibility that simple nutrient depletion was
causing growth inhibition, some experiments were done using
a 1 :1 mixture of CM and RPMI containing twice the normal
nutrient concentration + FCS (final concentration FCS 20%).
The results were the same as those in Fig. 1.
Specificity of the CM Effect
CM was collected from exponential and confluent cultures
of BAEC, rat and calf SMC, and BHK cells as described in
Materials and Methods. The volume of medium used for
conditioning was 1 m1/106 cells. All cell types tested for their
responsiveness to CM were plated as described in Materials
and Methods, except that BHK cells were arrested using 0.2%
CS for 60 h. Rat SMC used in these experiments were second
or third passage; calf SMC were first or second passage. BAEC
were first through fifth passage, except that the confluent
BAEC-CM was always collected from primary cultures. Cell
numbers in duplicate cultures were measured at daily intervals
after exposing cells to CM. The data are presented in Table I
as the maximum percent inhibition. We obtain this figure by
first subtracting the starting cell number (i.e., the cell number
at the time the cells are released from Go) from the cell number
at day 5, when growth has essentially ceased in both control
and CM-exposed cells, and any growth inhibition was therefore
maximal. The net growth in control cells is set at 100%, and
the net growth in CM-treated cells is expressed as a percentage
of the control. The difference is the maximum percent inhibi-
tion. We used this method ofexpressingour data to (a) compare
more readily growth inhibition in experiments using different
cell types or different types of CM, (b) to compare more easily
the effect of various physical and biochemical treatments on
the inhibitory activity, and (c) to calculate an EDso for heparin
and other substances with inhibitory activity.
Confluent, primary BAEC-CM preferentially inhibited rat
and calf SMC; BHK and BAEC were much less affected (Table
I). Other CM did not substantially inhibit SMC growth. It
should be pointed out that when exponential cells are put in
0.4% serum they begin the transition from proliferation to
quiescence. We cannot rule out the possibility that a growth
effector(s) secreted by truly exponential cells is lost or masked
during this transition. With this reservation in mind, the data
demonstrate an apparent specificity of the inhibitory activity
for both the producer and the target cell.
Serum Requirements for Release and
Effectiveness of the Inhibitory Activity
When we allowed confluent primary BAEC to condition
serum-free medium for 48 h, the inhibitory activity decreased
to 10-20% ofthe activity found in CM containing 0.4% serum.TABLE I
Specificity of the BAEC-CM Effect
Cells were tested for their response to CM as described in Materials and
Methods and Results. Thedata are presented as maximum percent inhibition.
0 means only that there was no inhibitory effect of CM. Exponential BAEC-
CM (described in text) stimulated cell growth when compared to normal
growth medium. Experiments involving BHK cells or BHK-CM were done
twice. All other combinations were done four or more times. In all cases, cells
in normal growth medium doubled four or more times before reaching
confluence.
TABLE II
Serum Requirement for BAEC-CM Effect
Maximum percent inhibition
10% CS +
10% CS
￿
20% CS
￿
10% FCS
￿
20% FCS
￿
10% FCS
-CM 0 0 42 20 12
+CM 34 30 91 87 80
Calf SMC were plated and growth-arrested as described in Materials and
Methods. Thecells were exposed to the indicated final concentrations of sera
with or without BAEC-CM. The data are from a representative experiment in
which the calf SMC exposed to CM did not round up and detach.
The overall metabolic rate of confluent BAEC in serum-free
medium as measured by the rate of protein synthesis was
decreased by only 30% (data not shown). This suggests that
production of the inhibitory activity by BAEC depends to a
large extent on the presence of serum. FCS and CS were
equally effective in releasing the inhibitory activity.
If growth-arrested calf SMC were exposed to a 1:1 mixture
of BAEC-CM and RPMI + FCS (final FCS concentration,
20%),thegrowth inhibition shownin Fig. 1 occurred. However,
if growth-arrested calf SMC were exposed to a 1:1 mixture of
BAEC-CM and DMEM + CS (final CS concentration, 10%),
much less inhibition was observed (Table II). Calf SMC are
usually grown in DMEM + 10% CS; when grown in RPMI +
20% FCS, they grow at a slightly slower rate and reach 80-90%
of the final cell density of calf SMC grown in DMEM + 10%
CS. Mixing CS and FCS does not block the inhibitory activity
(Table II). Growth-arrested calf SMC released into DMEM
+ 20% CS grow at the same rate as they do in DMEM + 10%
CS; the inhibitory effect of BAEC-CM when the final CS
concentration is 20% is similar to the effect when the final CS
concentration is 10% (Table II). When Go calf SMC are
exposed to RPMI + 10% FCS, they reach -60% of the final
cell density of calf SMC grown in DMEM + 10% CS. The
inhibitory effect of BAEC-CM when the finalFCS concentra-
tion is 10% is slightly greater than in 20% FCS because the
cells do notgo through even one doubling. These data suggest
that BAEC-CM interacts with something present in greater
concentrations in FCS than in CS to generate the inhibitory
activity. However, we cannot rule out the possibility that
substances present in CS compete with the SMC for the
inhibitor. Similar experiments cannot be done with rat SMC
because these cells do not grow well in CS. In summary, the
release of inhibitory activity by BAEC requires the presence of
a small amount of either FCS or CS; however, the inhibitory
effect is greater in the presence of FCS than in CS.
Effect of Passage Number
CM from confluent BAEC at differentpassages wascollected
as described in Materials and Methods. It was tested for
inhibitory activity on second or third passage rat SMC as
described in Materials and Methods. The results are presented
in Fig. 2A as the maximum percent inhibition. The data
demonstrate that the inhibitory activity in confluent BAEC-
CM decreases rapidly as the passage number of the BAEC
increases.
Fig. 2Bshows the results of experiments in whichconfluent
primary BAEC-CM was tested on rat SMC at different pas-
sages. These data show that the inhibition by BAEC-CM
decreases as the passage number of rat SMC increases. Calf
SMCwere always used betweenpassages oneandthreebecause
they tended to become pleiomorphic at laterpassages. We have
generally noted that third passage calf SMC were slightly less
responsive to BAEC-CM (not shown).
Ó
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FIGURE 2
￿
Effect of passage number on BAEC-CM effect. (A) The
effect of confluent BAEC-CM from the indicated passage numbers
on the growth of second or third passage rat SMC was assayed as
described in Materials and Methods. (B) The effect of confluent
primary BAEC-CM on the growth of rat SMCat the indicated passage
numbers was assayed as described in Materials and Methods. All
passage number data are the average of three or more experiments,
except for BAEC-CM at passages 6, 8 and 10, which were done
twice.
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Type of CM
Maximum percent inhibition
Rat
BHK BAEC SMC
Calf
SMC
None (normal growth me- 0 0 0 0
dium)
Exponential BHK 2 11 8 4
Confluent BHK 13 3 16 10
Exponential rat SMC 9 11 16 7
Confluent rat SMC 8 15 1 12
Exponential calf SMC 0 6 7 9
Confluent calf SMC 0 8 13 18
Exponential BAEC 7 0 0 1
Confluent BAEC 6 2 63 >80Biochemical Characterization of the
Inhibitory Activity
We subjected the CM obtained in 0.4% serum to a variety of
treatments to characterize it. To test the heat sensitivity of the
inhibitory activity, aliquots of CM were heated at 60°C for 30
min, or at 90°C for 5 min. CM treated this way lost <20% of
its activity (Table III).
To determine whether the inhibitory activity was a
protein(s), we treated it with 301Eg/ml trypsin for 2 h at 37°C.
A tenfold excess ofsoybean trypsin inhibitor in a small volume
was added 30 min before mixing the CM with RPMI + FCS
(final concentration FCS 20%). Separate aliquots of CM were
treated with 30 tLg/ml chymotrypsin for 2 h at 37°C, or with 30
leg/ml subtilisin (Carlsberg) for 60 min at 37°C. A tenfold
weight excess of chick egg white ovoinhibitor was added to the
chymotrypsin-treated CM at least 30 min before mixing the
CM with RPMI + FCS (final concentration FCS 20%). Sub-
tilisin-treated CM was heated at 90°C for 5 min to kill the
enzyme activity. Less than 10% of the inhibitory activity was
lost after these protease treatments (Table III). To control for
nonspecific protease or inhibitor effects, the same concentration
of proteases and inhibitors (or boiled enzyme in the case of
subtilisin) were mixed together for 30 min, then added to
RPMI + 20% FCS or the 1 :1 CM-RPMI + FCS (final concen-
tration FCS 20%) mixture. The inhibitory activity was unal-
tered by these treatments.
BAEC-CM was incubated with 1 U/ml of chondroitin ABC
lyase for 90 min at 37°C. Separate aliquots ofBAEC-CM were
treated with 15 U/ml hyaluronidase for 90 min at 37°C. The
samples were then boiled for 5 min, a treatment which kills the
enzyme activity but does not affect the inhibitory activity.
These enzyme treatments resulted in little or no loss of activity
(Table III). Boiled hyaluronidase or chondroitin ABC lyase
added to RPMI + 20% FCS did not affect SMC growth.
When BAEC-CM was incubated with 10 U/ml purified
Flavobacterium heparinase for 90 min at 37°C, 80% of the
inhibitory activity was lost (Table III). The heparinase prepa-
ration has no detectable protease activity, even when tested in
a sensitive assay system (17). In addition, the inhibitory activity
in BAEC-CM was insensitive to digestion by a broad range of
proteases, as described above. The heparinase is specific for a
heparin or heparinlike substrate, in that it requires a 1-4
linkage between sugar residues and also requires sulfated idu-
ronic acid or N-sulfated glucosamine as a substrate. Thus, it
will not degrade chondroitin sulfates, dermatan sulfate, or
hyaluronic acid. The inhibitory activity in BAEC-CM therefore
appears to be heparin or a heparinlike molecule.
Two other lines of evidence support this conclusion. First, a
crude isolate of glycosaminoglycans from BAEC-CM was pre-
pared by the method of Dietrich and de Oca (7). The TCA-
soluble, ethanol-precipitable material obtained was reconsti-
tuted in the starting volume of RPMI + 20% FCS. When rat
or calf SMC were exposed to this medium, their growth was
inhibited with the same kinetics displayed in Fig. 1, although
the calf SMC did not round up and detach in these experiments.
Treating the crude isolate of GAGS with heparinase destroyed
the inhibitory activity. GAGs isolated in the same manner
from unconditioned medium (i.e., RPMI + 0.4% FCS) had no
effect on SMC growth.
The second approach was to examine the effect ofexogenous
GAGS on SMC growth. When chondroitin sulfate ABC, der-
matan sulfate, hyaluronic acid, or two types of heparan sulfate
376
￿
THE JOURNAL OF CELL BIOLOGY " VOLUME 90, 1981
TABLE III
Biochemical Properties of the BAEC-CM Inhibitory Activity
CM from BAEC was subjected to the indicated treatments and then assayed
for its ability to inhibit growth-arrested calf and rat SMCwhen mixed 1 :1 with
RPMI + FCS (final concentration 20% FCS) . SD are given in those instances
when the treatments were performed three or more times. In other cases, the
treatments were performed twice.
[GAGl1ml
FIGURE 3
￿
Effect of GAGs on rat SMC growth. (A) Rat SMC were
plated and growth-arrested as described in Materials and Methods.
The cells were then exposed to RPMI + 20% FCS containing the
indicated concentrations of GAGS. Cell number was measured at
daily intervals. Data are expressed as maximum percent inhibition.
(B) Rat SMC were plated at 6 x 103/16-mm well . After 24 h, the
medium was aspirated and replaced with fresh RPMI + 20% FCS
with or without the indicated concentrations of GAGS. Data are
expressed as maximum percent inhibition. W-", heparin;
Q--f], bovine aortic heparan sulfate; H, beef lung heparan
sulfate; A-A, dermatan sulfate; A-A, chondroitin ABCsulfate;
0-0, hyaluronic acid . Data for the heparan sulfates are the
average of three experiments; data for other GAGS are the average
of five or more experiments.
Treatment
Maximum
Calf SMC
percent inhibi-
tion
Rat SMC
None 84 t 8 58 t 5
60° C, 30 min 76 ± 9 53 t 10
90° C, 5 min 93 ± 4 62 ± 5
Trypsin
(30 P,g/m1, 2 h, 37°C) 82 ± 5 60 ± 10
Chymotrypsin
(30Itg/ml, 2 h, 37°C) 85 54
Subtilisin
(30 jug/ml, 60 min, 37°C) - 51
Hyaluronidase
(15 U/ml, 90 min, 37°C) 94 ± 4 50
Chondroitin S04 ABC lyase
(1 U/ml, 90 min, 37°C) 88 ± 7 58 ± 2
Heparinase
(10 U/ml, 90 min, 37°C) 19 9 ± 6were added to either growth-arrested or exponential cultures
of rat SMC, no inhibition of growth occurred at concentrations
up to 10 ttg/ml (Fig. 3). At 100 ttg/ml, slight inhibition (up to
20°Io) of growth-arrested cells was observed with these GAGS
(Fig. 3). In contrast, heparin inhibited SMC growth by 50% at
1-2 ttg/ml in growth-arrested SMC, and at 90-100 ltg/ml in
exponential SMC (Fig. 3). Anticoagulant and non-anticoagu-
lant heparin (21) were equally effective in inhibiting SMC
proliferation.
Note that growth-arrested SMC are nearly 100 times more
sensitive to heparin than exponential SMC (Figs. 3 and 4).
Although the ED,o for heparin is rather variable from experi-
ment to experiment, the 100-fold difference in sensitivity to
heparin was very consistent.
We also examined the effect of heparin on BAEC growth.
Exponential and growth-arrested BAEC were not inhibited by
heparin at doses <100 ttg/ml (Fig. 4). There was actually a
slight stimulation of BAEC, which ranged from 10-30% in
different experiments. This is in sharp contrast to the effect of
heparin on SMC. Heparin did not affect the growth of either
exponential or growth-arrested BHK cells at doses <100 tLg/
ml (data not shown).
Mitogenic Activity in BAEC-CM
When we attempted to fractionate BAEC-CM on Amicon
filters, nearly all the inhibitory activity was lost. However, we
noticed a small but consistent increase in cell number when
the 10,000- to 100,000-dalton and >100,000-dalton fractions
were added to RPMI + 20% FCS. In light of the recent
observations by Gajdusek et al. (11) that BAEC secrete a SMC
mitogen, we fractionated CM from exponential BAEC at pas-
sages five through seven. The mitogenic potential of these
Amicon fractions was assayed on rat SMC as described in
Materials and Methods. The >100,000-dalton fraction sup-
ported two rounds of SMC division, whereas the 1% FCS (final
concentration) control supported less than one doubling (Fig.
5). The 10,000- to 100,000-dalton fraction had even greater
mitogenic activity, but the background from this fraction of
100
[HEPARINI/ml
FIGURE 4
￿
Effect of heparin on BAEC and rat SMC growth. Expo-
nential cultures of BAEC, and exponential and growth-arrested
cultures of rat SMC were obtained as described in Materials and
Methods. Growth-arrested BAEC were obtained by placing 6 x 103
BAEC growing in 16-mm wells in RPMI + 0.4% FCS for 72 h. These
cells were exposed to the indicated concentrations of heparin as
described in Fig. 3 . CEO, growth-arrested rat SMC; 0
￿
",
exponential rat SMC; A-A, growth-arrested BAEC; A-A, ex-
ponential BAEC. Data are the average of five or more experiments.
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FIGURE 5 Mitogenic activity in fractionated BAEC-CM. CM from
exponential BAEC (passages 5-7) was fractionated using Amicon
filters. The ability of a concentrated >100,000-dalton fraction
(~---") to stimulate the growth of Go-arrested rat SMC was
assayed as described in Materials and Methods, and compared to
growth in 20% FCS (0----0) and 1% FCS (final concentration) +
concentrated 0.4% FCS (A-"; see Materials and Methods). Data
are from a representative experiment.
concentrated RPMI + 0.4% FCS was also higher and more
variable. This is probably the result of concentrating the low
molecular weight growth factors, e.g., platelet factors, known
to be present in serum. The results from this fraction are thus
more difficult to interpret. These results confirm the observa-
tions of Gajdusek et al. (11) on the production of an SMC
mitogen by BAEC.
We have shown that cultured BAEC are capable of secreting
both positive and negative effectors of SMC growth. The
mitogen is probably similar to the one described by Gajdusek
et al. (11). The inhibitor appears to be heparin or a heparinlike
molecule. Using CM fromconfluent cultures ofprimary BAEC,
we observed a slow-onset inhibition of proliferation of growth-
arrested SMC (Fig. 1). The difference between our observations
of an inhibitory activity in BAEC-CM and those of Gajdusek
et al., in which a mitogenic activity dominates, are due likely
to one or more ofthe following differences in the systems used:
(a) we collected CM only from primary BAEC that have been
confluent for at least a week, whereas Gajdusek et al. used later
passage BAEC to collect CM; (b) we collected our CM in the
presence of serum, whereas Gajdusek et al. used plasma-de-
rived serum; and (c) we used growth-arrested SMC to assay for
inhibitory activity, whereas Gajdusek et al. used exponential
SMC to assay for mitogenic activity.
The issue' of cytotoxicity is difficult to address directly.
Several observations suggest that the inhibitory effect of
BAEC-CM is not strictly cytotoxic: (a) the rat SMC never
detach, and the calf SMC detach only two-thirds of the time in
experiments using 20% FCS; (b) experiments in which the final
concentration of FCS was varied suggest that the detachment
of calf SMC may be an artefact of serum concentrations; (c)
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calf SMC experiments in 20% FCS in which cells detach); (d)
daughter cells are able to spread normally aftercytokinesis; (e)
flow microfluorimetry shows that both control and CM-ex-
posed SMC have thesame cell cycle distribution at the end of
the experiment;V)
the CM-treated SMC nevertake up trypan
blue; and (g) the BAEC-CM effect is reversible. Even if the
growth inhibition is due to cytotoxicity, however, it is still
important, because the inhibitory activity is specific for both
producer and target cell (Table I). This type of specificity could
be important in: (a)thenormal vessel, inwhichthis mechanism
of SMC growth regulation may be involved in maintaining the
SMC in a quiescentgrowth state; (b) the injured vessel, where
the cessation of myointimal proliferation occurs after re-en-
dothelialization of the damaged area (9); and (c) regulation of
blood vessel morphogenesis during development and remod-
elingof thevasculature. Thelack ofinhibition ofBAEC growth
by BAEC-CM is corroborated by the observation that com-
mercially-prepared heparin, while inhibiting SMC prolifera-
tion, did not inhibit BAEC (Fig. 4) or BHK cells.
Serum is required forproduction ofthe heparinlike inhibitor
by BAEC. Thenature of the serumrequirement is notknown,
but at least two generalpossibilities exist: (a) serumprovides a
necessary biosynthetic precursor or cofactor for heparin syn-
thesis; and (b) serumprovides asubstancethat releases heparin
from the endothelial cell surface. Because heparan sulfate has
been shown to cause release of more heparan sulfate from the
cell surface (4, 5), it is possible that the serum provides either
heparan sulfate or an enzyme which liberates heparin. These
possibilities remain to be tested.
The secretion of a heparinlike inhibitor of SMC by BAEC
fits in well with observations made in this and otherlaborato-
ries. Buonassisi (3), Gamse et al. (12),andBusch et al. (5)have
shown that cultured BAEC secrete heparan sulfates (ofwhich
heparin may be considered a subclass). Indeed, about half of
all the GAGS synthesized by BAEC are heparan sulfates
secreted into the medium. In contrast, SMC and fibroblasts
secrete only -I0% of their GAGS as heparan sulfates (12, 20,
31). In addition, Gamse et al. (12) found that the heparan
secreted by BAEC was more heparinlike (i.e., more highly
sulfated) than the heparan made by bovine aortic SMC.
The BAEC must be confluent before the inhibitory activity
can be detected. Indeed, exponentially growingBAEC produce
a SMC mitogen (Fig. 5). We suggest that the cessation of
BAEC growth, may be an important step in the regulation of
vascular smooth muscle cell growth in vivo. This idea is
supported by recent observations that in a nonregenerating
(i.e., quiescent) vascular bed, heparan sulfates arethe predom-
inant cell-associated GAGS, whereas in an actively regenerat-
ing vascular bed, the amount of heparan sulfate is greatly
diminished (1).
When purified GAGS were added to growth-arrested SMC
cultures, heparin wasby farthemost potent inhibitorofgrowth
(Fig. 3). Preliminary experiments (not shown) suggestthat the
degree of sulfation plays an important role in the antiprolifer-
ative effect of heparin. This idea is supported by the fact that
the inhibitory activity of GAGS correlates with their degree of
sulfation; heparin has 2.5-3 sulfate groups per hexosamine;
lung heparan sulfate, dermatan sulfate, and chondroitin ABC
sulfate have about one sulfate per hexosamine; aortic heparan
sulfate and hyaluronic acid contain 0.3 and zero sulfates per
hexosamine, respecti'vely.
Theeffect ofheparin on SMCproliferation in vivo has been
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studied in this laboratory for several years. Clowes and Kar-
novsky (6), usingan air-dry model for vessel injury (9), showed
that heparin markedly suppressed myointimal proliferation
when infused in rats 24 h after the injury. More recently,
Guyton et al. (14), also using the air-dry model for vessel
injury, found that heparin preventedmyointimal proliferation,
and that anticoagulant and non-anticoagulant heparin were
equally effective. In a series of parallel studies, Hoover et al.
(18) demonstrated that heparin blocked the stimulation of
cultured rat SMC growth by platelet extract, and showed that
the inhibition was probably not mediated via a direct interac-
tion with platelet-derived growth factor. Again, anticoagulant
and non-anticoagulant heparin were equally effective. The
experiments using exogenous heparin and other GAGS re-
ported here confirm and extend these previous studies.
Based on the in vivo and in vitro demonstrations that non-
anticoagulant heparin is as potent as anticoagulant heparin in
inhibiting SMC growth, it is possible that non-anticoagulant
heparin might be useful in those clinical situations (balloon
embolectomy, endarterectomy, vein grafting, etc.) in which
suppression of myointimal proliferation is important to the
patient, becausethe problem of increased bleeding that accom-
panies the use of anticoagulant heparin would be avoided.
Synthetic, non-anticoagulant analogs of heparin which retain
their SMC antiproliferative capacity might also be useful. The
growth-arrested SMC assay would provide a good screening
system for developing such compounds.
Experiments arenow underway to examinethenature ofthe
serum requirement for production and release ofheparin from
BAEC, the chemical structureofantiproliferative heparin, and
the mechanism of heparin-induced inhibition of SMC prolif-
eration. This system should prove useful in elucidating the
molecular mechanisms involved in the regulation of vascular
cell growth.
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